PPPaola Edith Padilla-Noguera

Paola Edith Padilla-Noguera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paola Edith Padilla-Noguera has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Genotypes and Risk Factors for Anal Cytological Abnormalities in People Living With HIV and High‐Risk Human Papillomavirus: The GAIA 2 Study Cytological Abnormalities in People Living With HIV and High‐Risk Human Papillomavirus

    by Ana Luz Cano‐Díaz, Omar Hernández‐López, José Antonio Mata‐Marín, Javier Vicente Noyola‐Gómez, Sócrates Alberto García‐Gutiérrez, Ericka Nelly Pompa‐Mera, Brenda Clara González‐Contreras, Paola Edith Padilla‐Noguera, Alberto Chaparro‐Sánchez, Jesús Enrique Gaytan‐Martínez

    Background: Human papillomavirus (HPV) infection is a major risk factor for cervical, anal, and oropharyngeal cancers, particularly in people living with HIV (PWH), who face higher HPV prevalence, especially in men who have sex with men (MSM). Limited data on HPV in Mexican PWH highlight the need for targeted screening. Objective: To assess the prevalence of anal cytological abnormalities in PWH and their association with high‐risk HPV genotypes. Methods: A cross‐sectional study (2023–2025) at Hospital de Infectología ‘La Raza’, Mexico City, included 137 PWH with confirmed high‐risk HPV. Anal cytology and PCR based HPV genotyping for 28 genotypes were conducted. Multivariate logistic regression adjusted for confounders, including vaccination status. Results: Multiple high‐risk HPV genotypes (> 3) were linked to abnormal cytology (OR 3.094, 95% CI 1.297–7.383, p = 0.009) and ASC‐US (OR 3.060, 95% CI 1.177–7.954, p = 0.018). HPV 16+59 increased ASC‐US risk (OR 5.450, 95% CI 1.259–23.600, p = 0.032). Vaccination reduced risks for abnormal cytology (OR 0.331, 95% CI 0.116–0.948, p = 0.039) and ASC‐US (OR 0.209, 95% CI 0.053–0.823, p = 0.025). Conclusion: High‐risk HPV genotypes 16 and 59 and multiple HPV infections are risk factors for anal cytological abnormalities in PWH. Vaccination is protective, supporting enhanced screening and vaccination strategies to reduce HPV‐related cancer risks. Trial Registration: ClinicalTrials.gov identifier: R‐2025‐3502‐052

  • Effectiveness and safety of dolutegravir/lamivudine/abacavir versus bictegravir/emtricitabine/tenofovir alafenamide as first-line regimens in real-world settings (MICTLAN study)

    by José Antonio Mata-Marín, Mara Soraya Rodríguez-Evaristo, Ana Luz Cano-Díaz, María del Rosario Valenzuela-Salazar, Alberto Chaparro-Sánchez, Salma Triana-González, Omar Hernández-López, Ericka Nelly Pompa-Mera, Paola Edith Padilla-Noguera, Jesús Enrique Gaytán-Martínez

    Background: Integrase strand transfer inhibitor (INSTI)-based regimens, such as dolutegravir/lamivudine/abacavir (DTG/3TC/ABC) and bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), are recommended as first-line antiretroviral therapy (ART) for people living with HIV (PLH). This study compares their efficacy and safety in ART-naïve men living with HIV (MLH) in a real-world setting over 48 weeks. Methods: This open-label, randomized clinical trial (February 2021–October 2024) at Hospital de Infectología “La Raza” enrolled ART-naïve MLH with HIV-1 RNA ≥500 copies/mL and creatinine clearance >30 mL/min. Participants were randomized 1:1 to BIC/FTC/TAF or DTG/3TC/ABC. The primary endpoint was undetectable viral load (<50 copies/mL) at week 48, with safety assessed by adverse events (AEs) per DAIDS criteria. Results: Of 311 participants, 153 received BIC/FTC/TAF and 158 DTG/3TC/ABC. Virologic suppression was achieved in 90% of the BIC/FTC/TAF group and 86% of the DTG/3TCC/ABC group (p = 0.32). Median CD4+ counts were 649 cells/µL (BIC/FTC/TAF) and 723 cells/µL (DTG/3 TC/ABC) (p = 0.18). DTG/3TC/ABC had higher gastrointestinal AEs (21.5% vs 14.3%; p = 0.04) and grade 3 neuropsychiatric AEs. BIC/FTC/TAF showed higher insomnia rates. Abacavir-related hypersensitivity occurred in 0.6%. Conclusion: Both regimens showed high efficacy. BIC/FTC/TAF was more effective in patients with low baseline CD4 + counts, while DTG/3TC/ABC performed better with higher viral loads. DTG/3TC/ABC had more neuropsychiatric AEs and rare hypersensitivity reactions.

  • Open Access

    Prevalence and Associated Factors for HPV in People Living with HIV: Are INSTIs Protective Against HPV-16? The GAIA Study

    by Omar Hernández-López, Brenda Clara González-Contreras, Ana Luz Cano-Díaz, José Antonio Mata-Marín, Ericka Nelly Pompa-Mera, Javier Vicente Noyola-Gómez, Salma Triana-González, Paola Edith Padilla-Noguera, Alberto Chaparro-Sánchez, Sócrates Alberto García-Gutiérrez, et al.

    Human papillomavirus (HPV) significantly contributes to anogenital cancers, with elevated risks among people living with HIV (PWH), particularly men who have sex with men (MSM). This study assessed anal HPV prevalence and associated risk factors in PWH in Mexico, focusing on the role of antiretroviral therapy (ART). Methods: A cross-sectional study at an HIV clinic in Mexico City (October 2023–December 2024) enrolled 214 MSM with HIV. The participants completed a validated risk factor questionnaire and provided anal samples for real-time PCR testing of 28 HPV genotypes. Logistic regression analyzed associations between HPV infection, ART regimens, and clinical/behavioral factors. Results: HPV prevalence was 89.3%, with HPV-16 (20.1%) being the most common high-risk genotype. Integrase inhibitor (INSTI) use was inversely associated with HPV-16 infection (OR: 0.42; 95% CI: 0.21–0.83; p = 0.011), while protease inhibitor use increased HPV-16 (OR: 2.16; 95% CI: 1.09–4.29; p = 0.025) and HPV-6 risks. Higher CD4+ counts (≥500 cells/mm3) and undetectable HIV viral load (<40 copies/mL) were protective against multiple HPV genotypes. Lower education and smoking increased HPV risk. Conclusions: This first Mexican study in the ART and HPV vaccination era highlights high anal HPV prevalence in PWH and suggests that INSTI-based regimens may reduce HPV-16 risk, informing ART selection for HPV prevention.


  • Open Access

    High Prevalence of Asymptomatic STIs in MSM PWH in a Male HIV Clinic in Mexico City

    by Juan Pablo Sánchez Navarro, Gustavo Barriga Angulo, José Antonio Mata Marín, Mara Rodríguez Evaristo, Paola Edith Padilla Noguera, Jesús Enrique Gaytán Martínez

    Background: The incidence of sexually transmitted infections (STIs) remains high among men who have sex with men (MSM) living with human immunodeficiency virus (HIV) (PWH). This study determined the prevalence of asymptomatic STIs in MSM PWH attending an HIV clinic in Mexico City. Methods: This cross-sectional study (May 2022-November 2023) included self-questionnaires on STI-related behaviors and symptoms, urethral samples for multiplex polymerase chain reaction (PCR), and serological tests for syphilis, HBV, and HCV. Results: Among 261 patients, 56.7% were receiving antiretroviral therapy, 41.8% had suppressed HIV-1 viral load, and 26.1% tested positive for at least one STI in urethral PCR. The most prevalent microorganisms were Ureaplasma urealyticum (14.9%), Mycoplasma hominis (6.9%), Mycoplasma genitalium (4.2%), and Chlamydia trachomatis (3.1%). Multiple infections were identified in 5.3% of cases. Seroprevalence rates for syphilis, HBV, and HCV were 17.6%, 6.5%, and 3.1%, respectively. Current smoking and insertive anal sex were the only statistically significant associated factors. Conclusions: This study underscores the high frequency of asymptomatic STIs and the importance of regular screening.